Syndax Q4 revenue rises 38%, net income misses estimates

Syndax Pharmaceuticals

26/02/2026 21:21

Overview

Biopharmaceutical firm reported Q4 2025 revenue of $68.7 mln, driven by cancer therapies

Net loss for Q4 narrowed to $68 mln from $94.2 mln

Company completed enrollment in Phase 2 IPF trial of axatilimab

Outlook

Topline data from Phase 2 IPF trial expected in 4Q26

Company expects to initiate RAVEN trial in 2H26

Syndax projects total operating expenses of $400 mln for 2026

Result Drivers

FDA APPROVAL IMPACT - Revuforj revenue increased 38% in Q4 following FDA approval for R/R AML treatment

PRODUCT DEMAND - Niktimvo revenue rose 22% in Q4 due to increased demand and collaboration with Incyte

Company press release: ID:nGNX29PP3x

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Miss
-$68.01 mln
-$50.13 mln (11 Analysts)
Q4 Operating Expenses
$131.28 mln
Q4 Operating Income
-$62.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $38.00, about 83.1% above its February 25 closing price of $20.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)